GENE ONLINE|News &
Opinion
Blog

2022 psychedelics
Shifting From Counterculture to Clinical Applications, The Problems Psychedelics Face Getting to Market
2022-07-22
Refining Psychedelics into Medicine – An Interview with Doug Drysdale, CEO of Cybin
2022-04-19
The Renaissance of Psychedelics Research: An Interview with the CEO of MindMed, Rob Barrow
2022-04-12
WSJ Health Forum 2022: Psychedelics Set to Take Center Stage in Mental Wellness
2022-03-24
Low Doses of LSD as a Potential Treatment for Anxiety in the Future?
2022-03-22
History on Depression Therapy: the Past and the Psychedelic Future
2022-03-21
Cure or Poison? New Ventures Go IPO Continuously As “Psychedelics” Enter the Mental Health Market
2022-03-09
From Forbidden Drugs to Psychotropic Cures: A “Psychedelic Boom” Breaks New Ground in Treating Mental Illnesses
2022-03-08
LATEST
NDA for Biogen-Sage’s Zuranolone Accepted by FDA, Marking Another Step Forward in Depression Drug Development
2023-02-07
BMS Returns $475 Million Cancer Asset To Dragonfly Therapeutics
2023-02-07
FDA Expands Approval For Takeda’s Takhzyro To Prevent Hereditary Angioedema Attacks
2023-02-06
Abbott’s New Technologies for Arrhythmia Treatment Secure FDA and European Approval
2023-02-04
First Human Trial for Marburg Virus Vaccine Reports Success
2023-02-03
Karuna Licenses Goldfinch’s Mood Disorder Candidates For Potential $535 Million
2023-02-03
Novel Bioengineered Wearable Edgeless Skin Brings Hope to Revolutionize Plastic and Reconstructive Surgery
2023-02-03
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!